The galectins are a family of intra- and extracellular
galactoside-binding lectins that binds and at least
sometimes cross-links glycoconjugates. By doing so, they
play important roles in immune regulation, which in turn
manifests itself in rate-limiting roles in immunological
conditions and cancer. Lund University hosts a network of
several collaborating research groups with leading
activities ranging theoretical studies of galectin
proteins and their ligands to in vivo investigations of galectin
functions and involvement in disease mechanisms.
Theoretical studies of galectin-ligand complexes are
done in the research group of theoretical chemistry
professor Ulf Ryde.
Crystallographic studies of galectin-3 and its complexes
are performed by biostructural chemistry associate
NMR structural and dynamical investigations are done by
biophysical chemistry professor Mikael Akke.
Organic and medicinal chemistry of galectin ligands and
inhibitors are done by organic chemistry professor Ulf J.
Biomolecular mechanisms of galectins are studied the
research group of molecular medicine professor Hakon
Cell biology professor Stina Oredsson
investigates the roles of galectins and their inhibition
effects on tumor cells.
associate professor in neuroscience, investigates the role
of galectin 3 in microglia and its function in stroke and
Galecto Biotech AB
is a new Lund-based company developing galectin antagonist
as novel drugs.
Biostructures AB is a drug discovery and structural
biology CRO that has determined ultra-high resolution